Thinking of joining a study?

Register your interest

Become a volunteer?

NCT05873452 | ACTIVE NOT RECRUITING | Peripheral Arterial Disease

Kaitoh Atherectomy FIH
Sponsor:

Terumo Medical Corporation

Brief Summary:

This is a prospective, multi-center and single-arm clinical study to assess the initial safety and effectiveness of the Kaitoh Atherectomy System for the treatment of de novo and/or restenotic lesion(s) in the peripheral arteries.

Condition or disease

Peripheral Arterial Disease

Intervention/treatment

Kaitoh Atherectomy System

Phase

NA

Study Type : INTERVENTIONAL
Estimated Enrollment : 10 participants
Masking : NONE
Primary Purpose : TREATMENT
Official Title : Kaitoh Atherectomy System: Peripheral Artery Revascularization of Stenotic/Restenotic Disease Using the Atherectomy System in the Peripheral Arteries
Actual Study Start Date : 2023-08-07
Estimated Primary Completion Date : 2025-03-20
Estimated Study Completion Date : 2025-09

Information not available for Arms and Intervention/treatment

Ages Eligible for Study: 18 Years
Sexes Eligible for Study: ALL
Accepts Healthy Volunteers:
Criteria
Inclusion Criteria
  • * Age ≥18 years old
  • * Rutherford Classification: 3-5 in target limb; Rutherford Classification 3 subjects may be enrolled but will be capped to a limit of 20% of the total enrollment (no more than two Rutherford Class 3 subjects may be enrolled into the study).
  • * Able and willing to provide informed consent, and comply with follow-up visits at both 30 days and 180 days (6 months)
  • * Able to comply with antiplatelet therapy as required
  • * Reference Vessel Diameter is ≥2.0 mm and ≤4.0 mm
  • * Target lesion length is ≤150 mm
  • * De novo or restenotic target lesion(s) (except for in-stent restenotic lesion) with stenosis ≥70%, by visual estimation, in a single limb in a single native vessel
  • * Inflow artery is patent, free from significant lesion stenosis (≥50% stenosis is considered significant) as visually confirmed by angiography. Note: Successful inflow artery treatment is allowed during the index procedure. Successful inflow artery treatment is defined as attainment of residual diameter stenosis ≤50% without major vascular complications (absence of flow limiting dissection, embolic event)
  • * Guidewire has successfully crossed the target lesion(s) within the true lumen
Exclusion Criteria
  • * Females who are pregnant or lactating
  • * Pre-existing illness with life expectancy \<1 year
  • * Known or suspected systemic infection
  • * Significant gastrointestinal bleeding or any coagulopathy that would preclude the use of anti-platelet therapy
  • * Subjects with a diagnosis of osteomyelitis and are currently on IV antibiotic therapy
  • * Endovascular or surgical procedure performed on the target lesion within 3 months of the index procedure
  • * Subjects who in the opinion of the Investigator have underlying kidney disease and may be at risk for contrast-induced acute kidney injury (AKI)
  • * Subjects who in the opinion of the Investigator have uncontrolled diabetes
  • * Allergic to iodine/radiopaque contrast that in the opinion of the Investigator cannot be adequately pre-treated
  • * History of Coronary Artery Bypass Graft (CABG), unstable angina pectoris, or myocardial infarction within 30 days and/or hemorrhagic stroke within 90 days
  • * Subjects scheduled to undergo a planned major amputation of the lower limb above the ankle on the target limb
  • * Allergic to any of the components of the atherectomy device system
  • * Intraprocedural complications prior to use of the investigational device
  • * Subjects with a positive COVID-19 test within the last 60 days and/or is symptomatic, at the Investigator's discretion
  • * Subject with other medical, social or psychological problems that, in the opinion of the investigator, preclude them from receiving this treatment, and the procedures and evaluations pre - and post-treatment
  • * Presence of flow-limiting stenosis (\>50% diameter reduction) or occlusion of inflow vessels that was not successfully treated (\<50% residual stenosis without flow limiting dissection) before the study intervention/prior to the point of enrollment
  • * No obvious angiographic evidence of flow to the foot following inflow treatment
  • * Co-existing aneurysmal disease requiring treatment
  • * Presence of vessel dissection at the target lesion requiring stent placement
  • * Clinical/angiographic evidence of distal embolization or acute thrombus
  • * Severe calcification that is measured \>10mm in length and circumferential
  • * Prior stent placement in the target lesion
Kaitoh Atherectomy FIH

Location Details

NCT05873452

Please Choose a site

How to Participate

Want to participate in this study, select a site at your convenience, send yourself email to get contact details and prescreening steps.

Locations

Not yet recruiting

New Zealand,

Auckland Hospital

Auckland, New Zealand, 1023

Not yet recruiting

New Zealand,

Waikato Hospital

Hamilton, New Zealand,